Overall, this study established the physiological and pathological significance of the EP300-AS1-PTBP1-PRMT5 axis in NSCLC progression, suggesting that EP300-AS1 mimetics or PTBP1 inhibition may represent promising therapeutic strategies for NSCLC. Here, PRMT5 is linked to non-small cell lung carcinoma.